论文部分内容阅读
对于表皮生长因子受体(epidermal growth factor receptor,EGFR)突变的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC),表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptortyrosine kinase inhibitor,EGFR-TKI)已经成为一线治疗的优选方案。我院采用我国自主研发的小分子靶向药物埃克替尼125 mg,tid口服治疗了1例EGFR突变的晚期肺腺癌患者,10 d后患者症状明显缓解,1个月后双肺弥漫结节缩小、消失,疗效评价为稳定(stable disease,SD)。继续服药,每3个月定期复查,双肺结节继续缩小。用药11个月后出现肺部病灶缓慢长大,继续服药1个月后复查见肺部病灶仍继续缓慢长大,将埃克替尼加量,125 mg,tid及250 mg,tid交替口服。加量45 d后复查病灶再次得到控制。
For patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation, epidermal growth factor receptor tyrosine kinase inhibitor (epidermal growth factor receptor tyrosine kinase inhibitor , EGFR-TKI) has become the preferred option for first-line therapy. Our hospital with our own research and development of small molecule targeted drug Icitinib 125 mg, tid oral treatment of a case of EGFR mutation in patients with advanced lung adenocarcinoma, 10 days after the patient’s symptoms were significantly relieved, 1 month after diffuse bilateral pulmonary tuberculosis Day narrowed, disappeared, the curative effect was evaluated as stable disease (SD). Continue to take medication, regular review every 3 months, lung nodules continue to shrink. After 11 months of treatment, lung lesions grew slowly. One month after taking the medicine, pulmonary lesions continued to grow slowly. The doses of imatinib, 125 mg, tid and 250 mg of tid were alternately administered orally. Review the lesion again after 45 days.